Grants and Contributions:
Title:
Development and validation of in silico designed SARS-CoV-2 and Influenza combinatorial vaccines
Agreement Number:
1009618
Agreement Value:
$183,000.00
Agreement Date:
Aug 1, 2023 - Jun 30, 2024
Description:
The goal of this project is to test a proprietary in silico platform and vector system to design and validate vaccine formulations targeting Influenza and SARS-CoV-2.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
New Westminster, British Columbia, CA V3M 6B9
Reference Number:
172-2023-2024-Q2-1009618
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
732113931
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 61 days. The total amended value is 22,000 dollars.
Amendment Date
Mar 21, 2024
Recipient's Operating Name:
Eyam Vaccines and Immunotherapeutics Ltd.
Recipient's Legal Name:
Eyam Vaccines and Immunotherapeutics Ltd.
Federal Riding Name:
New Westminster--Burnaby
Federal Riding Number:
59019
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: